A burn patient on the operating table is about to lose a significant amount of blood. The surgeon reaches for a familiar tool: gauze soaked in saline to keep the wound moist during excision. But a randomized clinical trial published in the journal Burns suggests that swapping that saline for tranexamic acid, a cheap, widely available clot-stabilizing drug, can meaningfully reduce how much blood the patient loses. The trial found that patients whose wound surfaces were moistened with topical tranexamic acid (TXA) experienced significantly lower blood loss compared with those treated with standard saline, at a statistical threshold of p less than 0.05. The study does not report exact mean blood-loss figures or sample size in its publicly available abstract, so the precise magnitude of the reduction cannot be independently confirmed from that source alone.
The finding, which researchers reported in early 2025, is part of a broader shift in how surgeons think about bleeding control. Rather than delivering TXA through an IV line, as hospitals have done for decades, a growing number of trials are testing what happens when the drug is applied directly where it is needed: on the open wound itself.
A drug already in the cabinet, used in a new way
Tranexamic acid is not new. It has been a staple of emergency and surgical medicine for years, most notably after the landmark CRASH-2 trial demonstrated that intravenous TXA reduces death from bleeding in trauma patients. The World Health Organization lists it as an essential medicine. A vial typically costs a few dollars.
What is new is the delivery method. In the burn surgery trial, researchers did not inject TXA into a vein. They moistened the wound bed with it during excision, a step that takes seconds and requires no additional equipment. The control group received the same treatment with ordinary 0.9% sodium chloride. The TXA group bled less, and the study found no clear increase in postoperative infections during the follow-up period.
This approach had already shown promise in orthopedic surgery. A controlled trial published in the Journal of Bone and Joint Surgery found that instilling TXA directly into the surgical field before wound closure during knee replacement surgery reduced postoperative blood loss substantially compared with standard care. The study’s abstract reports a significant reduction in drainage and transfusion needs in the TXA group, though the exact percentage reduction is not specified in the publicly available abstract, so the commonly cited “roughly half” figure cannot be independently verified from that source. Surgeons in that study monitored drainage volumes and transfusion requirements, and the TXA group came out ahead on both measures.
The consistency across two very different surgical settings, burn excision and joint replacement, matters. It suggests that topical TXA works through a reliable biological mechanism (stabilizing clots at the wound surface) rather than through some quirk of one particular procedure.
Systematic reviews back the pattern
Individual trials can be compelling, but medicine puts the most trust in evidence that holds up across multiple studies. Two major evidence syntheses support the topical TXA findings.
An evidence review compiled for the UK’s National Institute for Health and Care Excellence (NICE) examined TXA delivered through several routes, including topical and intra-articular application, and reported reductions in both transfusion rates and total blood loss across procedures. Separately, a Cochrane systematic review by Ker and colleagues reached a similar conclusion: topical TXA reliably reduces bleeding and the need for blood transfusions in surgical patients.
These reviews draw on data from multiple randomized controlled trials, which means the benefits observed in single-center studies are not isolated results. They reflect a pattern.
The pipeline extends to skin cancer surgery
Researchers are now pushing topical TXA into new territory. A randomized trial registered on ClinicalTrials.gov is testing TXA-soaked dressings on wounds left by Mohs micrographic surgery, a precise layer-by-layer technique used to remove skin cancers while sparing as much healthy tissue as possible. Patients in the trial are randomized to receive either TXA dressings or standard wound care, with investigators tracking bleeding outcomes and complications.
As of May 2026, results from that trial have not yet appeared in a peer-reviewed journal. The ClinicalTrials.gov entry confirms the study design and planned endpoints, but no primary outcome data, such as hemostasis times, re-bleeding episodes, or cosmetic results, are publicly available. Until those findings are published and scrutinized, the case for topical TXA in dermatologic surgery rests on the broader evidence base rather than direct proof in that specific setting.
Still, the trial’s existence signals something important: clinicians see topical TXA as practical enough to test in outpatient dermatology, not just in operating rooms where large tissue areas are removed under general anesthesia.
The clotting question
Every benefit in medicine comes with a trade-off question, and for TXA, the concern is blood clots. The drug works by blocking the breakdown of clots, which is exactly why it stops bleeding. But that same mechanism raises a legitimate worry: could applying it to a wound surface trigger dangerous clotting elsewhere in the body, such as deep vein thrombosis or pulmonary embolism?
The Cochrane systematic review by Ker and colleagues flagged this uncertainty explicitly. Neither the burn surgery trial nor the orthopedic trial reported clear increases in thromboembolic events, but both studies had limited sample sizes and follow-up periods. Many enrolled patients were also receiving standard clot-prevention measures, such as compression devices or blood-thinning medications, which could mask any added risk from TXA on the wound.
For context, intravenous TXA has a well-established safety profile in large trials involving tens of thousands of patients. The CRASH-2 trial, which enrolled over 20,000 trauma patients, found no significant increase in vascular occlusive events with IV TXA. Whether topical application carries a similar or even lower risk (since less drug enters the bloodstream) is plausible but not yet proven by dedicated safety studies.
Infection risk also remains incompletely characterized. The burn excision trial tracked postoperative infections and found no red flags, but detailed microbiological data and long-term wound-healing records are not publicly available. It is plausible that reduced bleeding and smaller hematomas could actually lower infection risk, since pooled blood in a wound can serve as a breeding ground for bacteria. But that hypothesis needs more data before it becomes a selling point.
Dosing is still a guessing game
One practical barrier to widespread adoption is the lack of standardized dosing. The burn study moistened wound surfaces with TXA. The orthopedic trial instilled it into the wound cavity before closure. Concentrations, volumes, and contact times differed between protocols, and neither trial compared multiple dosing regimens head to head.
Whether the ideal concentration or exposure time varies by wound type, surgical specialty, or patient risk profile remains unknown. Surgeons who want to try topical TXA today would need to follow individual study protocols or rely on institutional experience. No unified dosing guideline exists, and none is likely to emerge until comparative dosing trials are completed.
What this means for patients facing surgery in spring 2026
For someone scheduled for burn excision, joint replacement, or skin cancer removal, the practical takeaway as of spring 2026 is straightforward: asking a surgeon about topical TXA is a reasonable conversation to have. The drug is inexpensive, already stocked in hospital pharmacies, and used intravenously in many surgical protocols. Applying it to a wound represents a change in delivery, not a new pharmaceutical product.
Reduced blood loss can lower the need for transfusions, which decreases exposure to donor blood products and their associated risks. Fewer intraoperative interruptions for bleeding control could shorten operative times and potentially reduce time under anesthesia. These are meaningful benefits, particularly for patients who are elderly, anemic, or undergoing large-surface-area procedures.
Whether topical TXA is appropriate in any individual case will depend on the type of surgery, the patient’s clotting history, and the surgeon’s familiarity with the emerging data. The evidence is strong enough to justify the conversation but not yet definitive enough to make it standard of care. As the Mohs surgery trial and future studies report their findings, that calculus is likely to shift, and a gauze pad soaked in a few dollars’ worth of TXA may become as routine as the saline it replaces.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
